Table 8.

Individual patient characteristics of patients with APML with TB

Leukemia characteristics
Serial number	Age/sex	Hematological diagnosis	Therapy	Phase of therapy	Neutropenia at time of diagnosis of TB	Interval (between leukemia and TB)	Outcome of leukemia	Impact of TB on therapy
P1	28/M	APML	ATO + ATRA	Induction	Yes	5 weeks	Remission	None
P2	28/F	APML	ATO + ATRA	Induction	Yes	5 weeks	Remission	None
P3	30/M	APML	ATO + ATRA	Induction	Yes	8 weeks	Remission	None
P4	55/F	APML	ATO + ATRA	Induction	Yes	3 weeks	Remission	None
P5	29/F	APML	ATO + ATRA f/b maintenance with 6Mercatopurine and Methotrexate	Maintenance	Yes	68 weeks	Remission	None
P6	23/M	APML	ATO + ATRA	Induction	Yes	Simultaneous	Remission	None
P7	55/M	APML	ATO + ATRA	Induction	Yes	5 weeks	Remission	None

Tuberculosis characteristics
Serial number	Organs involved	Site of isolation	Evidence of TB	Outcome of TB	Side effects of ATT	Follow up after diagnosis of TB
P1	Lung, mediastinal lymph nodes	Mediastinal node	FNA AFB positive	Improved	None	In remission at 74 weeks
P2	Lungs, mediastinal nodes	Mediastinal node	FNA AFB positive	Improved	None	In remission at 64 weeks
P3	Lungs, mediastinal node, pleura	Mediastinal node	FNA AFB positive	Improved	Hepatitis	In remission at 113 weeks
P4	Lungs, pleura	Pleural fluid	Clinicoradiologic	Improved	None	In remission at 64 weeks
P5	Lungs, pleura, pericardium, mediastinal lymph nodes, Intestine	Pleural, lung, intestine	AFB positive	Expired	–	TB diagnosed post mortem
P6	Lung	BAL fluid	AFB positive	Improved	None	54 weeks
P7	Lung, mediastinal lymph Node	Mediastinal Node	Gene Xpert positive	Improved	None	62 weeks

APML acute promyelocytic leukemia, TB tuberculosis, M male, F female, AFB acid fast bacilli, ATO arsenic tri oxide, ATRA all trans retinoic acid, ATT anti tubercular therapy, BAL broncho alveolar lavage, FNA fine needle aspiration